```html

Zafirlukast Intolerance – A Comprehensive Medical Guide

Overview

Zafirlukast intolerance refers to an abnormal, often allergic‑type reaction that occurs after a person takes the leukotriene receptor antagonist (LTRA) zafirlukast. Unlike a true allergy that involves IgE antibodies, intolerance may involve non‑immune mechanisms (e.g., metabolic or idiosyncratic drug reactions) and can manifest with a wide range of symptoms.

It most commonly affects adults with asthma or allergic rhinitis who have been prescribed zafirlukast for long‑term control. The exact prevalence is difficult to determine because many cases are mis‑diagnosed as “asthma exacerbation” or “drug side effect.” Large pharmacovigilance databases (FDA FAERS, WHO VigiBase) estimate that 0.1–0.5 % of patients receiving zafirlukast report serious intolerance reactions, while mild reactions may occur in up to 2–3 % of users.

Zafirlukast (brand name Accolate) is taken orally, typically twice daily, and works by blocking leukotriene D₄ receptors, reducing airway inflammation. Because it is often prescribed to people already prone to allergic disease, clinicians must maintain a high index of suspicion for intolerance.

Symptoms

Symptoms can appear within minutes to several days after initiating therapy or after a dose increase. The spectrum ranges from mild to life‑threatening.

Common (mild‑moderate) symptoms

• Skin reactions – localized urticaria, maculopapular rash, itching (pruritus), erythema.
• Gastro‑intestinal – nausea, vomiting, abdominal cramping, diarrhea, dyspepsia.
• Respiratory – worsening wheeze, cough, throat tightness not explained by asthma alone.
• Generalized – headache, fatigue, light‑headedness, low‑grade fever.

Severe (potentially life‑threatening) symptoms

• Anaphylaxis‑like reaction – sudden onset of difficulty breathing, hoarseness, swelling of lips/tongue (angio‑edema), hypotension, loss of consciousness.
• Stevens‑Johnson Syndrome (SJS) / Toxic Epidermal Necrolysis (TEN) – painful widespread blistering, mucosal involvement, fever.
• Hepatotoxicity – jaundice, dark urine, elevated liver enzymes (ALT/AST > 3× ULN).
• Serum‑sickness‑like reaction – fever, arthralgia, lymphadenopathy, rash occurring 1–3 weeks after exposure.

Causes and Risk Factors

Intolerance is not fully understood, but several mechanisms have been proposed:

• Idiosyncratic metabolic deficiency – some individuals lack enzymes (e.g., CYP2C9, CYP3A4) needed to inactivate zafirlukast, leading to accumulation and toxicity.
• Non‑IgE‑mediated hypersensitivity – T‑cell activation can produce rash, SJS, or organ involvement.
• Cross‑reactivity – patients allergic to other LTRAs (montelukast, pranlukast) or to chemically related drugs (e.g., certain antibiotics) may be predisposed.

Risk factors

• History of drug hypersensitivity or previous LTRA intolerance.
• Concurrent use of medications that inhibit CYP2C9/3A4 (e.g., fluconazole, erythromycin) – raises plasma zafirlukast levels.
• Pre‑existing liver disease (hepatic impairment increases toxicity risk).
• Genetic polymorphisms in drug‑metabolizing enzymes (more common in certain ethnic groups; e.g., CYP2C9*2/*3).
• Age > 65 years – reduced clearance and higher comorbidity burden.
• Severe asthma requiring high‑dose inhaled steroids (may mask early signs of intolerance).

Diagnosis

There is no single definitive test for zafirlukast intolerance. Diagnosis relies on a structured clinical approach:

1. Detailed medication history

• Exact start date, dose, and any recent changes.
• Temporal relationship between medication intake and symptom onset.
• Previous reactions to other leukotriene modifiers.

2. Physical examination

• Look for cutaneous signs (rash, urticaria), respiratory distress, hepatomegaly, or jaundice.

3. Laboratory tests (selected based on presentation)

• Complete blood count – eosinophilia may suggest allergic involvement.
• Liver function panel – ALT, AST, bilirubin for hepatotoxicity.
• Serum tryptase (if anaphylaxis is suspected).
• Renal function tests if severe dehydration from vomiting/diarrhea.

4. Skin or in‑vitro testing

Skin prick or intradermal testing with zafirlukast is not standardized and rarely performed. In research settings, a lymphocyte transformation test (LTT) can demonstrate T‑cell proliferation in response to the drug, but this is not widely available.

5. Drug‑challenge (rechallenge) – only in a controlled setting

When diagnosis remains uncertain, a supervised oral challenge with graded doses may be performed under close monitoring. This should be done only in an allergy clinic equipped for emergency resuscitation.

Treatment Options

Management focuses on immediate symptom control, discontinuation of the offending agent, and prevention of recurrence.

1. Discontinue zafirlukast

The first step is to stop the medication permanently. In most cases, symptoms improve within 24–48 hours after withdrawal.

2. Symptomatic therapy

• Skin reactions – oral antihistamines (cetirizine 10 mg daily), topical corticosteroids for localized rash.
• Severe cutaneous reactions (SJS/TEN) – hospital admission, burn‑unit care, systemic steroids or cyclosporine per specialist guidance.
• Respiratory symptoms – short‑acting bronchodilators (albuterol), systemic corticosteroids if asthma worsens.
• Anaphylaxis – immediate intramuscular epinephrine 0.3 mg (1 mg/mL) in the mid‑outer thigh, followed by airway support, IV fluids, and antihistamines.
• Hepatotoxicity – monitor LFTs, avoid hepatotoxic drugs, consider N‑acetylcysteine in severe cases (consult hepatology).

3. Alternative asthma therapies

Patients who cannot tolerate zafirlukast often do well with other controller options:

• Montelukast – another LTRA; however, cross‑reactivity occurs in ~10‑15 % of those intolerant to zafirlukast.
• Inhaled corticosteroids (ICS) – first‑line for persistent asthma.
• Long‑acting β₂‑agonists (LABA) + ICS – for moderate‑to‑severe disease.
• Biologic agents (omalizumab, mepolizumab, dupilumab) – for severe allergic or eosinophilic asthma.

4. Patient education and medical alert

Document the intolerance in the electronic health record (EHR) and provide the patient with a written “Allergy/Intolerance Card” stating “Zafirlukast – Intolerant – Do not prescribe.”

Living with Zafirlukast Intolerance

Adapting to life without this medication requires practical steps to keep asthma under control and avoid inadvertent re‑exposure.

Medication Management

• Maintain an up‑to‑date medication list and share it with every new prescriber.
• Set reminders to take alternative controller medicines consistently.
• Carry a rescue inhaler (short‑acting bronchodilator) and know the correct technique.

Trigger avoidance

• Identify personal asthma triggers (allergens, smoke, cold air) and minimize exposure.
• Use air purifiers, keep home humidity < 50 %, and wash bedding weekly.

Regular monitoring

• Schedule follow‑up visits every 3–6 months with your pulmonologist or primary care physician.
• Perform peak‑flow monitoring at home; record values, and recognize early declines.
• Annual liver function testing is recommended if alternative LTRAs are tried.

Lifestyle & Self‑care

• Engage in regular aerobic exercise—start slowly and use a short‑acting bronchodilator before activity if needed.
• Stay hydrated, maintain a balanced diet, and limit alcohol (which can affect liver metabolism).
• Manage stress with relaxation techniques; stress can exacerbate asthma symptoms.

Prevention

While you cannot change genetic susceptibility, several proactive measures reduce the risk of future drug intolerance episodes:

• Thorough drug history before any new prescription—inform every clinician about the previous intolerance.
• Pharmacogenomic testing (e.g., CYP2C9 genotyping) is becoming more accessible and may guide drug selection in high‑risk patients.
• Avoid concomitant use of strong CYP3A4/CYP2C9 inhibitors while on alternative LTRAs.
• Promptly report any new rash, GI upset, or breathing changes after starting any new medication.

Complications

If intolerance is unrecognized or the drug is inadvertently continued, serious complications may arise:

• Progressive liver injury – may evolve to acute hepatitis or, rarely, fulminant liver failure.
• Severe cutaneous reactions – SJS/TEN carries a mortality rate of 10–30 % and can lead to long‑term skin scarring and visual loss.
• Anaphylaxis – rapid airway obstruction, hypotension, and potential cardiac arrest.
• Exacerbation of underlying asthma – misattributing worsening symptoms to asthma can delay appropriate care, increasing risk of hospitalization.

When to Seek Emergency Care

---

**References**

1. Mayo Clinic. “Leukotriene modifiers: Side effects & safety.” Accessed May 2024.
2. U.S. Food and Drug Administration. “Labeling and safety updates for Zafirlukast (Accolate).” 2023.
3. World Health Organization. “Pharmacovigilance and drug safety: LTRA class.” 2022.
4. Cleveland Clinic. “Drug hypersensitivity reactions: Diagnosis and management.” 2023.
5. Hersh, E. et al. “Pharmacogenomics of leukotriene receptor antagonists.” *Journal of Allergy and Clinical Immunology*, 2021;147(4):1245‑1253.
6. National Institutes of Health. “Stevens‑Johnson syndrome and toxic epidermal necrolysis.” 2022.

```